dr. scagliotti on mechanisms of resistance to egfr tkis
Published 12 years ago • 466 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
1:16
dr. scagliotti on treating egfr-mutated tumors with afatinib
-
4:28
overcoming resistance to egfr inhibitors in nsclc
-
5:46
resistance mechanisms in egfr nsclc
-
1:37
dr. scagliotti discusses egfr mutations in nsclc
-
1:41
osimertinib resistance in non-small cell lung cancer: pathways and potential solutions
-
6:02
egfr mutation and cancer
-
1:57
the egf receptor tyrosine protein kinases and the therapy of tumors with activated egf receptors. 02
-
4:32
resistance mechanisms in egfr-positive nsclc
-
0:54
dr. scagliotti on egfr targeted therapy survival benefits
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
2:20
dr. liu on resistance mechanisms in egfr-mutant lung cancer
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
1:00
dr. scagliotti discusses the future of lung cancer therapy
-
1:22
dr. scagliotti discusses the future of multiple gene profiles
-
1:49
dr. scagliotti on toxicities related to surgery and chemotherapy in patients with lung cancer
-
24:42
mechanisms of lung tumorigenesis by mutant egfr
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:17
dr. scagliotti gives 3 important lung cancer takeaway points
-
0:55
dr. giorgio scagliotti on combining targeted therapies with chemotherapy